• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠状病毒 M 和肠病毒 3C 特异性分析为广谱抗病毒化合物的开发提供了框架。

Profiling of coronaviral M and enteroviral 3C specificity provides a framework for the development of broad-spectrum antiviral compounds.

机构信息

Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wroclaw, Poland.

Institute of Molecular Medicine, University of Lübeck, Lübeck, Germany.

出版信息

Protein Sci. 2024 Sep;33(9):e5139. doi: 10.1002/pro.5139.

DOI:10.1002/pro.5139
PMID:39150063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328108/
Abstract

The main protease from coronaviruses and the 3C protease from enteroviruses play a crucial role in processing viral polyproteins, making them attractive targets for the development of antiviral agents. In this study, we employed a combinatorial chemistry approach-HyCoSuL-to compare the substrate specificity profiles of the main and 3C proteases from alphacoronaviruses, betacoronaviruses, and enteroviruses. The obtained data demonstrate that coronavirus Ms exhibit overlapping substrate specificity in all binding pockets, whereas the 3C from enterovirus displays slightly different preferences toward natural and unnatural amino acids at the P4-P2 positions. However, chemical tools such as substrates, inhibitors, and activity-based probes developed for SARS-CoV-2 M can be successfully applied to investigate the activity of the M from other coronaviruses as well as the 3C from enteroviruses. Our study provides a structural framework for the development of broad-spectrum antiviral compounds.

摘要

冠状病毒的主要蛋白酶和肠道病毒的 3C 蛋白酶在病毒多蛋白的加工中起着至关重要的作用,因此成为开发抗病毒药物的有吸引力的靶标。在这项研究中,我们采用组合化学方法-HyCoSuL-来比较甲型冠状病毒、乙型冠状病毒和肠道病毒的主要蛋白酶和 3C 蛋白酶的底物特异性谱。获得的数据表明,冠状病毒 Ms 在所有结合口袋中表现出重叠的底物特异性,而肠道病毒的 3C 对 P4-P2 位置的天然和非天然氨基酸表现出略有不同的偏好。然而,为 SARS-CoV-2 M 开发的化学工具,如底物、抑制剂和基于活性的探针,可以成功地应用于研究其他冠状病毒的 M 以及肠道病毒的 3C 的活性。我们的研究为开发广谱抗病毒化合物提供了结构框架。

相似文献

1
Profiling of coronaviral M and enteroviral 3C specificity provides a framework for the development of broad-spectrum antiviral compounds.冠状病毒 M 和肠病毒 3C 特异性分析为广谱抗病毒化合物的开发提供了框架。
Protein Sci. 2024 Sep;33(9):e5139. doi: 10.1002/pro.5139.
2
Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and cellular analysis.利用计算机模拟结构建模和细胞分析发现靶向病毒蛋白酶的广谱抗病毒药物。
Antiviral Res. 2025 Sep;241:106245. doi: 10.1016/j.antiviral.2025.106245. Epub 2025 Jul 29.
3
Synthesis and multitarget inhibitory effect of indole-based ethyl cinnamate derivatives against SARS-CoV-2 M and cathepsins for broad-spectrum anti-coronavirus activity.基于吲哚的肉桂酸乙酯衍生物对SARS-CoV-2 M蛋白和组织蛋白酶的合成及其多靶点抑制作用以实现广谱抗冠状病毒活性
Bioorg Med Chem. 2025 Oct 1;128:118258. doi: 10.1016/j.bmc.2025.118258. Epub 2025 May 23.
4
Generative adversarial network (GAN) model-based design of potent SARS-CoV-2 M inhibitors using the electron density of ligands and 3D binding pockets: insights from molecular docking, dynamics simulation, and MM-GBSA analysis.基于生成对抗网络(GAN)模型,利用配体电子密度和三维结合口袋设计强效严重急性呼吸综合征冠状病毒2(SARS-CoV-2)M蛋白抑制剂:分子对接、动力学模拟和MM-GBSA分析的见解
Mol Divers. 2024 Nov 30. doi: 10.1007/s11030-024-11047-9.
5
AI-driven covalent drug design strategies targeting main protease (m) against SARS-CoV-2: structural insights and molecular mechanisms.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(M)的人工智能驱动的共价药物设计策略:结构见解与分子机制
J Biomol Struct Dyn. 2024 Jan 29:1-29. doi: 10.1080/07391102.2024.2308769.
6
Ionic liquids and lysosomotropic detergents as inhibitors of the SARS-CoV-2 main protease: QSAR modeling, synthesis and biological testing.离子液体和溶酶体促透性去污剂作为严重急性呼吸综合征冠状病毒2主蛋白酶的抑制剂:定量构效关系建模、合成及生物学测试
Biochem Biophys Res Commun. 2025 Jun 28;777:152276. doi: 10.1016/j.bbrc.2025.152276.
7
Amphibian-Derived Peptides as Natural Inhibitors of SARS-CoV-2 Main Protease (M): A Combined In Vitro and In Silico Approach.源自两栖动物的肽作为严重急性呼吸综合征冠状病毒2主蛋白酶(M)的天然抑制剂:体外和计算机模拟相结合的方法
Chem Biodivers. 2025 Jun;22(6):e202403202. doi: 10.1002/cbdv.202403202. Epub 2025 Feb 6.
8
3CL of SARS-CoV-2 as a new target for bufadienolides: in silico and in vitro study.严重急性呼吸综合征冠状病毒2型的3CL作为蟾蜍二烯内酯的新靶点:计算机模拟和体外研究
J Comput Aided Mol Des. 2025 Jul 5;39(1):41. doi: 10.1007/s10822-025-00623-2.
9
Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M protein - an in silico and cell-based approach.揭示植物化学物质抑制新型冠状病毒M蛋白的潜力——基于计算机模拟和细胞的方法
Sci Rep. 2025 Jul 2;15(1):22840. doi: 10.1038/s41598-025-05907-z.
10
Novel SARS-CoV-2 allosteric inhibitors that destabilize the Main Protease M dimer.使主要蛋白酶M二聚体不稳定的新型严重急性呼吸综合征冠状病毒2变构抑制剂。
Int J Biol Macromol. 2025 Aug;319(Pt 1):145162. doi: 10.1016/j.ijbiomac.2025.145162. Epub 2025 Jun 12.

本文引用的文献

1
Structural basis for the inhibition of coronaviral main proteases by ensitrelvir.恩赛特韦抑制冠状病毒主蛋白酶的结构基础。
Structure. 2023 Sep 7;31(9):1016-1024.e3. doi: 10.1016/j.str.2023.06.010. Epub 2023 Jul 7.
2
Therapeutic strategies for COVID-19: progress and lessons learned.COVID-19 的治疗策略:进展与经验教训。
Nat Rev Drug Discov. 2023 Jun;22(6):449-475. doi: 10.1038/s41573-023-00672-y. Epub 2023 Apr 19.
3
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.恩赛特韦对全球流行的 SARS-CoV-2 3CL 蛋白酶突变株有效。
Biochem Biophys Res Commun. 2023 Feb 19;645:132-136. doi: 10.1016/j.bbrc.2023.01.040. Epub 2023 Jan 14.
4
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学:免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
5
Ensitrelvir as a potential treatment for COVID-19.恩西他韦作为COVID-19的一种潜在治疗方法。
Expert Opin Pharmacother. 2022 Dec;23(18):1995-1998. doi: 10.1080/14656566.2022.2146493. Epub 2022 Nov 10.
6
From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.从重新利用到重新设计:将博赛布韦优化为 SARS-CoV-2 主蛋白酶的高效抑制剂。
Molecules. 2022 Jul 4;27(13):4292. doi: 10.3390/molecules27134292.
7
Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.冠状病毒主要蛋白酶与药物候选 PF-07321332 结合的结构基础。
J Virol. 2022 Apr 27;96(8):e0201321. doi: 10.1128/jvi.02013-21. Epub 2022 Apr 7.
8
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.S-217622 的发现:一种非共价的口服 SARS-CoV-2 3CL 蛋白酶抑制剂临床候选药物,用于治疗 COVID-19。
J Med Chem. 2022 May 12;65(9):6499-6512. doi: 10.1021/acs.jmedchem.2c00117. Epub 2022 Mar 30.
9
Viral proteases: Structure, mechanism and inhibition.病毒蛋白酶:结构、机制与抑制。
Enzymes. 2021;50:301-333. doi: 10.1016/bs.enz.2021.09.004. Epub 2021 Nov 17.
10
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.